Heart failure with mildly reduced ejection fraction (HFmrEF)
- SGLT2 inhibitor has strongest broad outcome evidence
- Treat congestion with diuretics
- HFrEF therapies may help, especially EF near 40%
- Control BP, AF, ischemia + obesity
- Reassess EF over time
- Prior HFrEF improvement usually warrants continuing GDMT
Use at a glance
- SGLT2 inhibitor has strongest broad outcome evidence
Practical pearls
- HFrEF therapies may help, especially EF near 40%
- Control BP, AF, ischemia + obesity
- Prior HFrEF improvement usually warrants continuing GDMT
Other practical pearls
- Treat congestion with diuretics
Monitoring / follow-up
Self-check
- Which therapy has the strongest broad outcome evidence in HFmrEF?
An SGLT2 inhibitor.
- How is congestion treated in HFmrEF?
Diuretics.
Drugs used for this (3)
All clinical uses · Open the interactive console ↗
